HRP20191111T1 - Uvjetno replicirajući citomegalovirusi kao cjepivo za cmv - Google Patents
Uvjetno replicirajući citomegalovirusi kao cjepivo za cmv Download PDFInfo
- Publication number
- HRP20191111T1 HRP20191111T1 HRP20191111TT HRP20191111T HRP20191111T1 HR P20191111 T1 HRP20191111 T1 HR P20191111T1 HR P20191111T T HRP20191111T T HR P20191111TT HR P20191111 T HRP20191111 T HR P20191111T HR P20191111 T1 HRP20191111 T1 HR P20191111T1
- Authority
- HR
- Croatia
- Prior art keywords
- cmv
- composition
- patient
- conditionally defective
- defective replication
- Prior art date
Links
- 241000701022 Cytomegalovirus Species 0.000 title claims 11
- 230000003362 replicative effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 230000002950 deficient Effects 0.000 claims 6
- 230000010076 replication Effects 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 3
- 210000002919 epithelial cell Anatomy 0.000 claims 3
- NMFHJNAPXOMSRX-PUPDPRJKSA-N [(1r)-3-(3,4-dimethoxyphenyl)-1-[3-(2-morpholin-4-ylethoxy)phenyl]propyl] (2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate Chemical compound C([C@@H](OC(=O)[C@@H]1CCCCN1C(=O)[C@@H](CC)C=1C=C(OC)C(OC)=C(OC)C=1)C=1C=C(OCCN2CCOCC2)C=CC=1)CC1=CC=C(OC)C(OC)=C1 NMFHJNAPXOMSRX-PUPDPRJKSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 101150110861 TRM2 gene Proteins 0.000 claims 1
- 101150063032 UL51 gene Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001127 pigmented epithelial cell Anatomy 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Citomegalovirus (CMV) s uvjetno defektnom replikacijom sa destabiliziranim IE1/2 i UL51 proteinima, naznačen time što je genom CMV predstavljen sa SEQ ID NO: 14.
2. Kompozicija koja sadrži imunološki efikasnu količinu CMV s uvjetno defektnom replikacijom prema patentnom zahtjevu 1 i farmaceutski prihvatljiv nosač.
3. Kompozicija prema patentnom zahtjevu 2 koja dalje sadrži adjuvans.
4. Imunološki efikasna količina kompozicije prema patentnom zahtjevu 2 ili 3 za uporabu u postupku za indukciju imunološkog odgovora protiv CMV kod pacijenta.
5. Kompozicija za uporabu prema patentnom zahtjevu 4, naznačena time što je imunološki odgovor zaštitni imunološki odgovor kod pacijenta protiv CMV infekcije.
6. Kompozicija za uporabu prema patentnom zahtjevu 4 ili 5, naznačena time što pacijent ima oslabljeni imunitet.
7. Kompozicija za uporabu prema patentnom zahtjevu 4 ili 5, naznačena time što je pacijent žena u reproduktivnom dobu.
8. Upotreba CMV s uvjetno defektnom replikacijom prema patentnom zahtjevu 1 u proizvodnji lijeka za indukciju zaštitnog imunološkog odgovora kod pacijenta protiv CMV infekcije.
9. CMV sa uvjetno defektnom replikacijom prema patentnom zahtjevu 1 za uporabu u medicini za liječenje CMV infekcije kod pacijenta.
10. Postupak za pripremu CMV s uvjetno defektnom replikacijom koji sadrži umnožavanje rekombinantnog CMV prema patentnom zahtjevu 1 u epitelnim stanicama u prisustvu Shield-1, pri čemu je Shield-1 prisutan u koncentraciji od najmanje 0.5 µM.
11. Postupak prema patentnom zahtjevu 10, naznačen time što su epitelne stanice humane pigmentirane retinalne epitelne stanice.
12. Postupak prema patentnom zahtjevu 11, naznačen time što su humane retinalne pigmentirane epitelne stanice ARPE-19 stanice deponirane kod American Type Culture Collection (ATCC) kao pristupni br. CRL-2302.
13. Kompozicija koja sadrži imunološki efikasnu količinu CMV sa uvjetno defektnom replikacijom prema patentnom zahtjevu 1 u puferu na pH između 5-7 koja sadrži:
(a) između 15-35 mM histidina; i
(b) između 100-200 mM NaCl.
14. Kompozicija prema patentnom zahtjevu 13 naznačena time što pufer sadrži 25 mM histidina sa 150 mM NaCl na pH od 6.
15. Kompozicija prema patentnom zahtjevu 14 koja dalje sadrži 9% mas./zapr. saharoze.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532667P | 2011-09-09 | 2011-09-09 | |
| EP17171651.7A EP3251700B1 (en) | 2011-09-09 | 2012-09-04 | A conditional replicating cytomegalovirus as a vaccine for cmv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191111T1 true HRP20191111T1 (hr) | 2019-09-20 |
Family
ID=47832753
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171120TT HRP20171120T1 (hr) | 2011-09-09 | 2017-07-20 | Uvjetno replicirajući citomegalovirus kao cjepivo za cmv |
| HRP20191111TT HRP20191111T1 (hr) | 2011-09-09 | 2019-06-18 | Uvjetno replicirajući citomegalovirusi kao cjepivo za cmv |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171120TT HRP20171120T1 (hr) | 2011-09-09 | 2017-07-20 | Uvjetno replicirajući citomegalovirus kao cjepivo za cmv |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9546355B2 (hr) |
| EP (3) | EP3251700B1 (hr) |
| JP (1) | JP5926804B2 (hr) |
| KR (1) | KR101668163B1 (hr) |
| CN (1) | CN103889462B (hr) |
| AR (1) | AR087772A1 (hr) |
| AU (1) | AU2012304783B2 (hr) |
| BR (1) | BR112014005404A8 (hr) |
| CA (1) | CA2846870C (hr) |
| CL (1) | CL2014000541A1 (hr) |
| CY (2) | CY1119107T1 (hr) |
| DK (2) | DK2753364T3 (hr) |
| ES (2) | ES2633190T3 (hr) |
| HR (2) | HRP20171120T1 (hr) |
| HU (2) | HUE035322T2 (hr) |
| IL (1) | IL231272B (hr) |
| IN (1) | IN2014CN01809A (hr) |
| LT (2) | LT3251700T (hr) |
| ME (2) | ME02831B (hr) |
| MX (1) | MX353037B (hr) |
| NZ (1) | NZ622156A (hr) |
| PE (1) | PE20141525A1 (hr) |
| PL (2) | PL3251700T3 (hr) |
| PT (2) | PT2753364T (hr) |
| RS (2) | RS56261B1 (hr) |
| RU (2) | RU2670012C1 (hr) |
| SG (1) | SG11201400419YA (hr) |
| SI (2) | SI2753364T1 (hr) |
| TR (1) | TR201910644T4 (hr) |
| TW (1) | TWI570240B (hr) |
| UA (1) | UA114896C2 (hr) |
| WO (1) | WO2013036465A2 (hr) |
| ZA (1) | ZA201401708B (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2929034A4 (en) * | 2012-12-04 | 2016-06-22 | Merck Sharp & Dohme | VIRUS VECTORS WITH CONDITIONAL REPLICATION |
| US9868777B2 (en) | 2013-06-10 | 2018-01-16 | Merck Sharp & Dohme Corp. | CMV neutralizing antigen binding proteins |
| CA2955306C (en) | 2014-07-16 | 2021-06-01 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CA3079828A1 (en) * | 2017-11-01 | 2019-05-09 | Merck Sharp & Dohme Corp. | Stable formulations of cytomegalovirus |
| US20210047626A1 (en) * | 2018-04-24 | 2021-02-18 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US20220090005A1 (en) | 2019-01-03 | 2022-03-24 | Merck Sharp & Dohme Corp. | Supplemented Serum-Containing Culture Medium for Enhanced Arpe-19 Growth and Human Cytomegalovirus Vaccine Production |
| AU2020312560A1 (en) * | 2019-07-12 | 2022-03-03 | Danmarks Tekniske Universitet | Fusion toxin proteins for treatment of diseases related to CMV infections |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN112481222B (zh) * | 2020-11-30 | 2024-01-02 | 中国医学科学院医学生物学研究所 | 一种条件复制型重组单纯疱疹病毒、疫苗及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1150712T3 (da) * | 1999-02-05 | 2009-02-02 | Merck & Co Inc | Vaccineformuleringer mod human papillomavirus |
| ES2429338T3 (es) | 2002-12-23 | 2013-11-14 | Vical Incorporated | Vacuna basada en polinucleótidos optimizados por codones contra infección por citomegalovirus humano |
| US20060110406A1 (en) * | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
| US20040228842A1 (en) * | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
| NZ580974A (en) * | 2005-02-18 | 2011-05-27 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
| WO2007146024A2 (en) | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| US9439960B2 (en) * | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
| US8530636B2 (en) * | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
-
2012
- 2012-09-03 TW TW101132064A patent/TWI570240B/zh active
- 2012-09-04 LT LTEP17171651.7T patent/LT3251700T/lt unknown
- 2012-09-04 SI SI201231003T patent/SI2753364T1/sl unknown
- 2012-09-04 UA UAA201403638A patent/UA114896C2/uk unknown
- 2012-09-04 EP EP17171651.7A patent/EP3251700B1/en active Active
- 2012-09-04 PL PL17171651T patent/PL3251700T3/pl unknown
- 2012-09-04 ME MEP-2017-157A patent/ME02831B/me unknown
- 2012-09-04 CA CA2846870A patent/CA2846870C/en active Active
- 2012-09-04 JP JP2014529788A patent/JP5926804B2/ja active Active
- 2012-09-04 US US14/343,637 patent/US9546355B2/en active Active
- 2012-09-04 PT PT128303468T patent/PT2753364T/pt unknown
- 2012-09-04 EP EP12830346.8A patent/EP2753364B1/en active Active
- 2012-09-04 RS RS20170715A patent/RS56261B1/sr unknown
- 2012-09-04 WO PCT/US2012/053599 patent/WO2013036465A2/en active Application Filing
- 2012-09-04 PT PT17171651T patent/PT3251700T/pt unknown
- 2012-09-04 MX MX2014002815A patent/MX353037B/es active IP Right Grant
- 2012-09-04 KR KR1020147008959A patent/KR101668163B1/ko active IP Right Grant
- 2012-09-04 PL PL12830346T patent/PL2753364T3/pl unknown
- 2012-09-04 SI SI201231634T patent/SI3251700T1/sl unknown
- 2012-09-04 DK DK12830346.8T patent/DK2753364T3/en active
- 2012-09-04 TR TR2019/10644T patent/TR201910644T4/tr unknown
- 2012-09-04 PE PE2014000323A patent/PE20141525A1/es active IP Right Grant
- 2012-09-04 RU RU2017102888A patent/RU2670012C1/ru active
- 2012-09-04 ES ES12830346.8T patent/ES2633190T3/es active Active
- 2012-09-04 ME MEP-2019-176A patent/ME03488B/me unknown
- 2012-09-04 NZ NZ622156A patent/NZ622156A/en unknown
- 2012-09-04 ES ES17171651T patent/ES2737852T3/es active Active
- 2012-09-04 AU AU2012304783A patent/AU2012304783B2/en active Active
- 2012-09-04 RU RU2014113921A patent/RU2611198C2/ru active
- 2012-09-04 HU HUE12830346A patent/HUE035322T2/en unknown
- 2012-09-04 BR BR112014005404A patent/BR112014005404A8/pt not_active Application Discontinuation
- 2012-09-04 HU HUE17171651A patent/HUE045115T2/hu unknown
- 2012-09-04 RS RS20190753A patent/RS58891B1/sr unknown
- 2012-09-04 DK DK17171651.7T patent/DK3251700T3/da active
- 2012-09-04 SG SG11201400419YA patent/SG11201400419YA/en unknown
- 2012-09-04 LT LTEP12830346.8T patent/LT2753364T/lt unknown
- 2012-09-04 CN CN201280053360.7A patent/CN103889462B/zh active Active
- 2012-09-04 IN IN1809CHN2014 patent/IN2014CN01809A/en unknown
- 2012-09-04 AR ARP120103253A patent/AR087772A1/es active IP Right Grant
- 2012-09-04 EP EP19175776.4A patent/EP3572096A1/en active Pending
-
2014
- 2014-03-02 IL IL231272A patent/IL231272B/en active IP Right Grant
- 2014-03-06 CL CL2014000541A patent/CL2014000541A1/es unknown
- 2014-03-07 ZA ZA2014/01708A patent/ZA201401708B/en unknown
-
2017
- 2017-07-20 HR HRP20171120TT patent/HRP20171120T1/hr unknown
- 2017-07-20 CY CY20171100780T patent/CY1119107T1/el unknown
-
2019
- 2019-06-18 HR HRP20191111TT patent/HRP20191111T1/hr unknown
- 2019-08-06 CY CY20191100836T patent/CY1121863T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191111T1 (hr) | Uvjetno replicirajući citomegalovirusi kao cjepivo za cmv | |
| Biswas et al. | Bovine herpesvirus-1 (BHV-1)–a re-emerging concern in livestock: a revisit to its biology, epidemiology, diagnosis, and prophylaxis | |
| Gershwin | Immunology of bovine respiratory syncytial virus infection of cattle | |
| RU2661408C2 (ru) | Вакцинная композиция для применения в популяциях субъектов с ослабленным иммунитетом | |
| Zheng et al. | Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses | |
| Quinlivan et al. | Clinical and molecular aspects of the live attenuated Oka varicella vaccine | |
| Chowdhury et al. | A triple gene mutant of BoHV-1 administered intranasally is significantly more efficacious than a BoHV-1 glycoprotein E-deleted virus against a virulent BoHV-1 challenge | |
| US10548966B2 (en) | Single-cycle virus for the development of canine influenza vaccines | |
| Jones et al. | Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine | |
| Gai et al. | Immunization with recombinant rabies virus expressing Interleukin-18 exhibits enhanced immunogenicity and protection in mice | |
| US10857224B2 (en) | Equine influenza virus live attenuated vaccines | |
| Wang et al. | Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice | |
| Joshi et al. | Protective efficacy of an orf virus-vector encoding the hemagglutinin and the nucleoprotein of influenza A virus in swine | |
| Na et al. | Influenza virus vaccine for neglected hosts: horses and dogs | |
| CN108025055B (zh) | 多价肠道病毒疫苗组合物及其相关用途 | |
| Wei et al. | Bovine herpesvirus type 1 (BHV-1) mutant lacking UL49. 5 luminal domain residues 30–32 and cytoplasmic tail residues 80–96 induces more rapid onset of virus neutralizing antibody and cellular immune responses in calves than the wild-type strain Cooper | |
| Bouguyon et al. | A new adjuvant combined with inactivated influenza enhances specific CD8 T cell response in mice and decreases symptoms in swine upon challenge | |
| JP2012517239A5 (hr) | ||
| Stroh et al. | Henipavirus-like particles induce a CD8 T cell response in C57BL/6 mice | |
| Silva et al. | Vaccination with a gE-negative bovine herpesvirus type 1 vaccine confers insufficient protection to a bovine herpesvirus type 5 challenge | |
| Tao et al. | Th1-type epitopes-based cocktail PDDV attenuates hepatic fibrosis in C57BL/6 mice with chronic Schistosoma japonicum infection | |
| Suradhat et al. | Transdermal delivery of plasmid encoding truncated nucleocapsid protein enhanced PRRSV-specific immune responses | |
| Pyo et al. | Protective efficacy of intranasally administered bivalent live influenza vaccine and immunological mechanisms underlying the protection | |
| KR20120032486A (ko) | 면역화 요법용 발현 벡터로서의 수포성 구내염 바이러스의 상이한 혈청형 | |
| Röhrs et al. | A model for early onset of protection against lethal challenge with highly pathogenic H5N1 influenza virus |